ViraferonPeg 유럽 연합 - 크로아티아어 - EMA (European Medicines Agency)

viraferonpeg

merck sharp dohme ltd  - пэгинтерферон alfa-2b - hepatitis c, kronični - Иммуностимуляторы, - adults (tritherapy)viraferonpeg in combination with ribavirin and boceprevir (tritherapy) is indicated for the treatment of chronic-hepatitis-c (chc) genotype-1 infection in adult patients (18 years of age and older) with compensated liver disease who are previously untreated or who have failed previous therapy. molimo vas, obratite se ribavirin i боцепревир kratke specifikacije robe (smpcs), kada viraferonpeg se koristi u kombinaciji s ovi lijekovi. adults (bitherapy and monotherapy)viraferonpeg is indicated for the treatment of adult patients (18 years of age and older) with chc who are positive for hepatitis-c-virus rna (hcv-rna), including patients with compensated cirrhosis and / or co-infected with clinically stable hiv. viraferonpeg u kombinaciji s ribavirinom (bitherapy) indiciran za liječenje ХГС-infekcije kod odraslih pacijenata koji nisu prethodno tretirani tretman, uključujući i bolesnike s klinički stabilan hiv-infekcije i kod odraslih pacijenata koji nisu prethodno liječenje interferonom alfa (пегилированным ili пегилированным) i ribavirinom kombinirana terapija ili монотерапия interferonom alfa. Монотерапия interferonom, uključujući viraferonpeg, navedeno je u slučaju netolerancije ili kontraindikacija za рибавирину. molimo vas, obratite se Смпц ribavirinom, kada viraferonpeg se koristi u kombinaciji s ribavirinom. paediatric population (bitherapy)viraferonpeg is indicated in a combination regimen with ribavirin for the treatment of children three years of age and older and adolescents, who have chronic hepatitis c, previously untreated, without liver decompensation, and who are positive for hcv-rna. donošenju odluke da se neće odgoditi liječenje do odrasle dobi, važno je uzeti u obzir da je kombinirana terapija uzrokuje zadržavanje rasta, koji može biti nepovratan u nekih bolesnika. odluka mora biti donesena na individualnoj osnovi. molimo vas, obratite se Смпц ribavirin kapsule ili usmeno rješenje, kada viraferonpeg se koristi u kombinaciji s ribavirinom.

Flosteron 7 mg/ml suspenzija za injekciju 크로아티아 - 크로아티아어 - HALMED (Agencija za lijekove i medicinske proizvode)

flosteron 7 mg/ml suspenzija za injekciju

krka - farma d.o.o., radnička cesta 48, zagreb, hrvatska - natrijev betametazonfosfat betametazondipropionat - suspenzija za injekciju - 2 mg+5 mg/1 ml - urbroj: 1 ml suspenzije za injekciju (1 ampula) sadrži 2 mg betametazona u obliku natrijevog betametazonfosfata i 5 mg betametazona u obliku betametazondipropionata

Penon 1000 mg filmom obložene tablete 크로아티아 - 크로아티아어 - HALMED (Agencija za lijekove i medicinske proizvode)

penon 1000 mg filmom obložene tablete

alpha-medical d.o.o., dragutina golika 36, zagreb, hrvatska - fenoksimetilpenicilinkalij - filmom obložena tableta - 1000 mg - urbroj: jedna filmom obložena tableta sadrži 1000 mg fenoksimetilpenicilina u obliku fenoksimetilpenicilinkalija

Penon 800 mg filmom obložene tablete 크로아티아 - 크로아티아어 - HALMED (Agencija za lijekove i medicinske proizvode)

penon 800 mg filmom obložene tablete

alpha-medical d.o.o., dragutina golika 36, zagreb, hrvatska - fenoksimetilpenicilinkalij - filmom obložena tableta - 800 mg - urbroj: jedna filmom obložena tableta sadrži 800 mg fenoksimetilpenicilina u obliku fenoksimetilpenicilinkalija

FLOSTERON 5 mg/1 mL+ 2 mg/1 mL suspenzija za injekciju 보스니아 헤르체고비나 - 크로아티아어 - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

flosteron 5 mg/1 ml+ 2 mg/1 ml suspenzija za injekciju

krka farma d.o.o. sarajevo - betamethasone - suspenzija za injekciju - 5 mg/1 ml+ 2 mg/1 ml - 1 ml suspenzije za injekciju sadrži: 2,0 mg betametazona (u obliku betametazon fosfatnatrijuma 5,0 mg betametazona (u obliku betametazon dipropionata)

Jayempi 유럽 연합 - 크로아티아어 - EMA (European Medicines Agency)

jayempi

nova laboratories ireland limited - azathioprine - odbacivanje transplantata - imunosupresivi - jayempi is indicated in combination with other immunosuppressive agents for the prophylaxis of transplant rejection in patients receiving allogenic kidney, liver, heart, lung or pancreas transplants. azathioprine is indicated in immunosuppressive regimens as an adjunct to immunosuppressive agents that form the mainstay of treatment (basis immunosuppression). jayempi is used as an immunosuppressant antimetabolite either alone or, more commonly, in combination with other agents (usually corticosteroids) and/ or procedures which influence the immune response. jayempi is indicated in patients who are intolerant to glucocorticosteroids or if the therapeutic response is inadequate despite treatment with high doses of glucocorticosteroids, in the following diseases:severe active rheumatoid arthritis (chronic polyarthritis) that cannot be kept under control by less toxic agents (disease-modifying anti-rheumatic -medicinal products – dmards)auto-immune hepatitis systemic lupus erythematosusdermatomyositispolyarteritis nodosapemphigus vulgaris and bullous pemphigoidbehçet’s diseaserefractory auto-immune haemolytic anaemia, caused by warm igg antibodieschronic refractory idiopathic thrombocytopenic purpurajayempi is used for the treatment of moderately severe to severe forms of chronic inflammatory bowel disease (ibd) (crohn’s disease or ulcerative colitis) in patients in whom glucocorticosteroid therapy is necessary, but where glucocorticosteroids are not tolerated, or in whom the disease is untreatable with other common means of first choice. it is also indicated in adult patients in relapsing multiple sclerosis, if an immunomodulatory therapy is indicated but beta interferon therapy is not possible, or a stable course has been achieved with previous treatment with azathioprine. 3jayempi is indicated for the treatment of generalised myasthenia gravis. depending on the severity of the disease, jayempi should be given in combination with glucocorticosteroids because of slow onset of action at the beginning of treatment and the glucocorticosteroid dose should be gradually reduced after several months of treatment.